Turning back to the ongoing dramas around psychopharmaceuticals, in this case antidepressants a new rapid acting form of antidepressant has been approved for use in the US by the FDA. It is a combo of dextromethorphan and bupropion. medscape.com/viewarticle/979…

FDA Approves 'Rapid-Acting' Oral Drug for Major Depression

The US Food and Drug Administration has approved dextromethorphan-bupropion (Auvelity), the first for an NMDA receptor antagonist for the treatment of major depressive disorder in adults.

medscape.com
1
1
1
Dextromethorphan is already a drug of abuse. Bupropion is , an existing SSRI. It is weird timing considering the well-known problems with ssris and the debunking of the serotonin theory. It adds yet another Arsenal in the US for big Pharmaceutical profits and patient dangers.
1
2
Any patients with depression should be very careful when considering this new drug. If you are a provider get with the reality that a new era of understanding is upon us that these medications do great harm. What is the advantage of adding another? Profit. #a11y #prescribedharm

Aug 23, 2022 · 12:03 AM UTC
4